Sreenath V. Sharma

发表

Systematic identification of genomic markers of drug sensitivity in cancer cells

S. Ramaswamy, M. Stratton, P. Futreal, 2012, Nature.

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

D. Haber, Sreenath V. Sharma, J. Settleman, 2010, Nature Reviews Cancer.

A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay.

Sreenath V. Sharma, S. Akinaga, T. Mizukami, 2004, Biochemical pharmacology.

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Ben S. Wittner, B. Wittner, S. Ramaswamy, 2010, Cell.

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

A. Iafrate, Xiao-Jun Ma, M. Erlander, 2007, Proceedings of the National Academy of Sciences.

Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

Sreenath V. Sharma, J. Settleman, 2007, Genes & development.

Epidermal growth factor receptor mutations in lung cancer

Daniel A. Haber, D. Haber, Sreenath V. Sharma, 2007, Nature Reviews Cancer.

High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.

Ultan McDermott, U. McDermott, Sreenath V. Sharma, 2008, Methods in enzymology.

UCS15A, a non-kinase inhibitor of Src signal transduction

Sreenath V. Sharma, T. Tamaoki, H. Nakano, 2001, Oncogene.

“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

M. Fischbach, D. Haber, Sreenath V. Sharma, 2006, Clinical Cancer Research.

Stereospecific antitumor activity of radicicol oxime derivatives

M. Shimizu, Sreenath V. Sharma, L. Neckers, 2001, Cancer Chemotherapy and Pharmacology.

A structure-guided approach to creating covalent FGFR inhibitors.

Scott B Ficarro, Nathanael S Gray, Matthew Meyerson, 2010, Chemistry & biology.

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.

J. Korn, Sreenath V. Sharma, D. Ruddy, 2015, Cancer research.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Patricia L. Harris, Allan Wissner, Thomas J Lynch, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.

P. Majumder, Sreenath V. Sharma, J. Settleman, 2009, Gastroenterology.

Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol

Sreenath V. Sharma, H. Nakano, T. Agatsuma, 1998, Oncogene.

Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".

Sreenath V. Sharma, J. Settleman, 2010, Biochemical pharmacology.

Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe

E. Dmitrovsky, Patricia Greninger, Sreenath V. Sharma, 2010, Clinical Cancer Research.

Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer

Sreenath V. Sharma, J. Settleman, Anurag Singh, 2008 .

ErbBs in lung cancer.

Sreenath V. Sharma, J. Settleman, 2009, Experimental cell research.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Gayatry Mohapatra, D. Haber, Sreenath V. Sharma, 2005, Nature Genetics.

Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy

Kwok-Kin Wong, Sreenath V. Sharma, J. Settleman, 2010, Disease Models & Mechanisms.

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

D. Haber, Sreenath V. Sharma, J. Settleman, 2006, Cancer cell.

BASIC—LIVER, PANCREAS, AND BILIARY TRACT Inhibition of -Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

P. Majumder, Sreenath V. Sharma, J. Settleman, 2009 .

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

D. Haber, L. Sequist, Sreenath V. Sharma, 2008, Clinical Cancer Research.

UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug

Sreenath V. Sharma, H. Nakano, C. Oneyama, 2002, Oncogene.

Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A.

Sreenath V. Sharma, H. Nakano, C. Oneyama, 2003, Chemistry & biology.

Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-activated Aberrant Signaling Pathway*

K. Irie, Sreenath V. Sharma, Kunihiro Matsumoto, 1998, The Journal of Biological Chemistry.

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

S. Digumarthy, J. Neal, L. Sequist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Ultan McDermott, Hannah Stubbs, T. Shioda, 2008, Cancer research.

Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction

Sreenath V. Sharma, 1998, Oncogene.

A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation

Sreenath V. Sharma, J. Settleman, D. Frank, 2011, Oncotarget.

“Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell

Sreenath V. Sharma, J. Settleman, 2006, Cell cycle.

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

A. Iafrate, Xiao-Jun Ma, M. Erlander, 2009, Cancer research.

Allosteric inhibition of BCR-ABL

M. Warmuth, Sreenath V. Sharma, A. Q. Hassan, 2010, Cell cycle.

Development of radicicol analogues.

Sreenath V. Sharma, S. Soga, S. Akinaga, 2003, Current cancer drug targets.

Drug-target identification from total cellular lysate by drug-induced conformational changes.

K. Yano, Sreenath V. Sharma, H. Nakano, 2009, Analytical biochemistry.

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

W. Sellers, F. Lombardo, W. Jahnke, 2014 .

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

D. Haber, Sreenath V. Sharma, J. Settleman, 2005, Cold Spring Harbor symposia on quantitative biology.

Melittin-induced hyperactivation of phospholipase A2 activity and calcium influx in ras-transformed cells.

Sreenath V. Sharma, S. Sharma, 1993, Oncogene.

Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones.

Sreenath V. Sharma, L. Neckers, S. Akinaga, 1999, Molecular endocrinology.

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

T. Shioda, U. McDermott, D. Haber, 2008, Cancer research.

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.

Joshua M. Korn, Sreenath V. Sharma, D. Ruddy, 2015, Cancer research.